Lipitor, Atorvastatin
Lipitor, Atorvastatin Newswire

Lipitor, Atorvastatin Newswire

Comprehensive Real-Time News Feed for Lipitor, Atorvastatin (generic).

Results 1 - 20 of 244 in Lipitor, Atorvastatin (generic)

  1. High-dose statin treatment can help restore sightRead the original story

    Monday Feb 8 | Newkerala.com

    London, Feb 8 : A common cholesterol-lowering drug statin can restore vision in the patients with a hard-to-treat version of the leading cause of blindness in the developed world, according to a new research. Researchers at Massachusetts Eye and Ear/Harvard Medical School and the University of Crete have conducted a phase I/II clinical trial investigating the efficacy of statins for the treatment of patients with the dry form of age-related macular degeneration .

    Comment?

  2. Macular Degeneration: Doctors May Be Able To Treat Condition With...Read the original story w/Photo

    Sunday Feb 7 | Medical Daily

    High doses of atorvastatin may be able to treat age-related macular degeneration - one of the leading cause of blindness in the U.S.

    Comment?

  3. Statins have a darker sideRead the original story w/Photo

    Sunday Feb 7 | Yahoo!

    Over the past month there has been a series of reports in credible international medical journals detailing new concerns about how statins negatively affect people who are seen as being at risk of heart diseases - as opposed to those who have suffered cardiac incidents already. None of these reports got any coverage in the Australian news media, despite being well reported in Britain and elsewhere.

    Comment?

  4. High-Dose Statins May Ease Macular Degeneration for SomeRead the original story w/Photo

    Friday Feb 5 | MedicineNet

    High doses of cholesterol -lowering statin drugs -- medicines such as Lipitor , Crestor and Zocor -- may help people with a common eye disease called macular degeneration , a small study suggests. In the early stage clinical trial, a team from Harvard Medical School assessed the effects of statin treatment in people with the dry form of age-related macular degeneration .

    Comment?

  5. Patients with macular degeneration show improvement with high-dose statin treatmentRead the original story w/Photo

    Friday Feb 5 | Medical News Today

    Researchers at Massachusetts Eye and Ear/Harvard Medical School and the University of Crete have conducted a phase I/II clinical trial investigating the efficacy of statins for the treatment of patients with the dry form of age-related macular degeneration -- the leading cause of blindness in the developed world. Although effective treatments are available for the wet form of AMD, they are currently lacking for the more prevalent dry form.

    Comment?

  6. Atorvastatin in improvement of cognitive impairments caused by...Read the original story

    Wednesday Feb 3 | BioMed Central

    The production of inflammatory cytokines resulting from amyloid AZA2 is associated with the initiation of Alzheimer's disease . Atorvastatin has been reported to improve AD, however, it is unclear how the anti-inflammatory mechanism is linked with its protection against the impairment of spatial cognitive function in AD.

    Comment?

  7. High-dose Lipitor statin treatment could restore sight, say scientistsRead the original story w/Photo

    Thursday Feb 4 | Lancaster and MoreCambe Citizen

    A common cholesterol-lowering drug can restore vision to patients with a hard-to-treat version of the leading cause of blindness in the developed world, research has shown. High-dose treatment with the statin Lipitor cleared away fatty deposits behind the retina, leading to visual improvement in 10 patients with age-related macular degeneration .

    Comment?

  8. Statins May Ease Macular Degeneration for SomeRead the original story w/Photo

    Thursday Feb 4 | WebMD

    Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

    Comment?

  9. Statins May Offer Hope for BlindnessRead the original story w/Photo

    Thursday Feb 4 | News Max

    About 15 million people in the U.S. suffer from age-related macular degeneration , which is the leading cause of blindness and central vision loss in people age 65 and older. Now researchers from Mass.

    Comment?

  10. Could STATINS help restore vision? Drugs found to clear away...Read the original story w/Photo

    Thursday Feb 4 | Daily Mail

    An estimated 20 million people worldwide suffer with dry age-related macular degeneration - known as dry AMD - a disease which causes blurred vision and eventually blindness. Known as the 'Alzheimer's of the eye' because of the way it robs elderly people of their sight, the condition affects a quarter of British over-60s.

    Comment?

  11. Statin drug could restore eyesight to patients with common form of blindness, say scientistsRead the original story w/Photo

    Thursday Feb 4 | Mirror.co.uk

    Researchers looking for a treatment for age-related macular degeneration found a high dosage of Lipitor clears fatty deposits from the eye The team have been working on age-related macular degeneration , a leading cause of blindness in the developed world which is difficult to treat. They found a high-dosage of the statin Lipitor, which is used for millions of heart and cholesterol patients, cleared away fatty deposits behind the retina, leading to visual improvement in 10 patients.

    Comment?

  12. Patients with High-Risk Macular Degeneration Show Improvement with High-Dose Statin TreatmentRead the original story

    Thursday Feb 4 | Newswise

    A phase I/II clinical trial at Massachusetts Eye and Ear found that some patients taking high doses of atorvastatin had complete resolution of lipid deposits in the dry form of age-related macular degeneration . AMD is the leading cause of blindness in the developed world, and though effective treatments are available for the wet AMD, they are currently lacking for the more-prevalent dry form.

    Comment?

  13. Pfizer earnings fall but tops Street 4Q forecastsRead the original story w/Photo

    Tuesday Feb 2 | KMIR 6

    Pfizer Inc.'s fourth-quarter profit fell by half due to higher costs for production, administration and restructuring, but new revenue from an acquisition helped the world's second-biggest drugmaker beat Wall Street expectations. The New York-based company's revenue rose by 7 percent, ending a long stretch of declining sales due to generic competition to one-time blockbusters.

    Comment?

  14. Relationship between regulatory T cells subsets and lipid profile in...Read the original story

    Thursday Jan 28 | BioMed Central

    Atherosclerosis is now considered an inflammatory disease and it is well established that plaque initiation and destabilization are strictly linked with mechanisms involving both circulating and vascular immune cells and mediators of inflammation [ Atherosclerotic lesions initiate with endothelial damage and the proatherogenic potential of T cells is crucial in the progression from fatty streaks to mature plaques [ ].

    Comment?

  15. Alexander Says Despite Extra $1 Billion To Speed Generic Drug Approvals, FDA Process Still Too SlowRead the original story

    Thursday Jan 28 | Chattanoogan.com

    The chairman of the Senate health committee Thursday said that despite the Food and Drug Administration receiving an extra $1 billion in fees from the generic drug user fee program, the agency has slowed down its pace of approving generic drugs - threatening the program's ability to increase competition and lower the price of drugs for patients.

    Comment?

  16. Brand Name Statins Still Favored by Consumers: Treato Ranks Top...Read the original story

    Wednesday Jan 27 | Freshnews

    Today Treato , a leading consumer healthcare website, revealed their first annual list of top statins. This ranking is part of a new series of drug rankings from the company.

    Comment?

  17. Amgen's Repatha (Evolocumab) Approved As First PCSK9 Inhibitor In...Read the original story

    Thursday Jan 21 | BioSpace

    Repatha is a human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol , or "bad" cholesterol, from the blood.1 Repatha was developed in by Amgen Astellas BioPharma K.K. , a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical company headquartered in , Repatha is indicated for the treatment of patients with familial hypercholesterolemia or hypercholesterolemia who have high risk of cardiovascular events and do not adequately respond to HMG-CoA reductase inhibitors . , M.D., executive vice president of Research and Development at Amgen.

    Comment?

  18. Wen-Xin Decoction ameliorates vascular endothelium dysfunction via...Read the original story

    Friday Jan 22 | BioMed Central

    Nitric oxide is the most powerful vasodilator that inhibits leukocyte adhesion, platelet aggregation, and vascular smooth muscle cell proliferation. However, excessive NO can cause lipid peroxidation and direct endothelial cell damage.

    Comment?

  19. Atorvastatin Lactone (Cas 125995-03-1) Industry 2016 Global and Chinese Market Research ReportRead the original story

    Saturday Jan 23 | Emailwire.com

    WiseGuyReports.com adds 'Global and Chinese Atorvastatin Lactone Industry, 2016 Market Research Report' new report to its research database. The report spread across 150 pages with table and figures.

    Comment?

  20. Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in JapanRead the original story w/Photo

    Thursday Jan 21 | Medical News

    Amgen today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha Injection, the first proprotein convertase subtilisin/kexin type 9 inhibitor to be approved in Japan. Repatha is a human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol , or "bad" cholesterol, from the blood.

    Comment?